Denosumab (Prolia, Xgeva▼): Risk of osteonecrosis of jaw and external auditory canal

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Denosumab is a human monoclonal IgG2 antibody. Denosumab (Prolia▼) 60 mg solution for injection is indicated for for the treatment of osteoporosis in postmenopausal women and for the treatment of bone loss associated with hormone ablation and prostate cancer for men at increased fracture risk. Denosumab (Xgeva▼) 120 mg solution for injection is indicated for the prevention of skeletal-related events like pathological fracture, radiation to bone, spinal cord compression, or surgery to bone in adults with bone metastases from solid tumours, and for the treatment of adults with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity.

Five cases of osteonecrosis of the external auditory canal have been reported with use 60 mg denosumab. Th...